Apotex Inc., a leading Canadian pharmaceutical company, is headquartered in Toronto, Ontario, Canada. Founded in 1974, Apotex has established itself as a key player in the global generic and specialty pharmaceuticals industry, with a strong presence in North America, Europe, and other international markets. The company is renowned for its extensive portfolio of over 300 generic medications, which are designed to provide affordable alternatives to brand-name drugs. Apotex's commitment to quality and innovation has led to significant milestones, including the development of complex generics and biosimilars. With a robust manufacturing infrastructure and a focus on research and development, Apotex has achieved a notable market position, consistently ranking among the top generic drug manufacturers in Canada and worldwide. Its dedication to improving patient access to essential medications underscores its reputation as a trusted leader in the pharmaceutical sector.
How does Apotex's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Apotex's score of 37 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Apotex reported total carbon emissions of approximately 40,219,000 kg CO2e for Scope 1 and about 15,572,000 kg CO2e for Scope 2. This marks a slight decrease from 2022, where emissions were approximately 42,950,000 kg CO2e for Scope 1 and about 16,173,000 kg CO2e for Scope 2. Over the past few years, Apotex has shown a commitment to reducing its carbon footprint, with ongoing evaluations of potential pathways to decarbonisation for both Scope 1 and Scope 2 emissions. The company aims to establish near-term emissions reduction targets by 2025, reflecting its dedication to achieving net-zero emissions in the future. Apotex's proactive approach aligns with industry standards for climate action, focusing on transparency and accountability in its sustainability efforts.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|
Scope 1 | 44,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 20,870,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Apotex is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.